Introduction
============

Obesity results from excess energy intake over energy expenditure. Currently obesity is a major worldwide health problem because of its rising prevalence and strong association with pathological disorders such as heart disease, type 2 diabetes, hypertension, and some forms of cancer.[@b1-ijn-9-301] In the field of food science, studies on obesity have focused on searching for food components that have the potential to suppress the accumulation of body fat and increase energy expenditure. Numerous natural products, including crude extracts and isolated compounds from plants, have been linked to the reduction of body weight and prevention of diet-induced obesity[@b2-ijn-9-301]

Oleoresin capsicum (OC) is an organic solvent extract of dried ripe red pepper, which is the fruit from plants in the genus *Capsicum*.[@b3-ijn-9-301] OC is widely used as a food additive for the preservation and enhancement of taste as it has little odor and a pungent taste. The ethanolic and butanolic capsicum extracts present various biological benefits, such as anti-cancer,[@b4-ijn-9-301] anti-oxidant, and anti-inflammatory properties.[@b5-ijn-9-301] Moreover, anti-obesity activity of methanol extract from hot pepper (*Capcisum annuum* L.) seeds has been observed in 3T3-L1 adipocytes with decreased glycerol-3-phosphate dehydrogenase (GPDH) activity and CCAAT-enhancer-binding protein (*C/EBP*)-*α* and *C/EBP*-*β* mRNA expression.[@b6-ijn-9-301] Currently, there are more than 100 compounds identified in OC, such as acids, esters, alcohols, aldehydes, ketones, and carotenoid pigments, as well as capsaicin analogs.[@b7-ijn-9-301] It is assumed that some of those components may exert beneficial effects on health in cooperation with each other; however, the application of OC is limited by some drawbacks, such as low solubility and poor bioavailability,[@b8-ijn-9-301] thus, biotechnologies have been considered to increase bioavailability of OC.

Nanoemulsions (radius\<100 nm) are used in the food industry to encapsulate, protect, and deliver lipophilic functional components.[@b9-ijn-9-301] The advantages of nanoemulsion are to improve water solubility, thermal stability, oral bioavailability, sensory attributes, and physiological performance.[@b10-ijn-9-301] Since some bioactive components are hardly soluble in aqueous systems, adding those ingredients to liquid food products is almost impossible or not sufficient for food fortification.[@b11-ijn-9-301] Furthermore, finding appropriate delivery systems is especially challenging for the food industry, compared to other fields such as pharmacy or cosmetics, since only a limited amount of ingredients can be used as encapsulation and stabilization material.[@b11-ijn-9-301] Therefore, the nanoemulsion delivery system available for barely soluble food components could be one solution to enhance health benefits to the consumer.

The aim of the present study was to investigate the effects of OC and nanoemulsion OC (NOC) on obesity in rats with high-fat (HF)-diet-induced obesity. Expression of genes related to adipogenesis, such as peroxisome proliferator-activated receptor (*PPAR*)-γ, sterol regulatory element-binding protein (*SREBP*)-1c, and fatty acid-binding protein 2 (*aP2*), were analyzed in white adipose tissue (WAT). The mRNA levels of *PPAR*-*α*, carnitine palmitoyltransferase (*CPT*)-1α, and uncoupling protein-2 (*UCP2*), involved in β-oxidation and thermogenesis, were evaluated. In addition, activities of AMP-activated protein kinase (AMPK) and GPDH were compared.

Materials and methods
=====================

Materials
---------

TRIzol® Reagent and Moloney murine leukemia virus (M-MLV) reverse transcriptase were obtained from Life Technologies (Carlsbad CA, USA). Universal SYBR® Green PCR Master Mix was obtained from Qiagen (Germantown, MD, USA). Kits for the analysis of aspartate aminotransferase (AST), alanine aminotransferase (ALT), triglycerides (TGs), and total cholesterol (TC) were purchased from Asan Pharmaceutical (Seoul, Korea). The AMPK Kinase Assay kit was purchased from CycLex (Nagano, Japan). A GPDH activity assay kit was purchased from Takara Bio (Kyoto, Japan). A bicinchoninic acid (BCA) protein assay kit was obtained from Thermo Fisher Scientific (Waltham, MA, USA). All other reagents were obtained from Sigma-Aldrich (St Louis, MO, USA).

Preparation and characterization of OC and NOC
----------------------------------------------

Samples (OC and NOC) were kindly supplied from Korea Food Research Institute (Songnam, Gyeonggi, Korea). In order to prepare the NOC, a pre-mixture was formulated by stirring 210 g of OC (General Foods and Flavors, Seoul, Korea) and 201 g of Tween 80, and the mixture was dispersed into 2,100 mL of purified water under mild stirring for 1 hour. The coarse emulsion was passed through an air-driven Microfluidizer® (model M-110L; Microfluidics, Westwood, MA, USA) operating at 25,000 psi for five cycles. The microfluidized sample was dispersed into 2,500 mL of 0.2% β-cyclodextrin solution for 2 hours using the syringe pump, and filtered with a 0.45 μm polyvinylidene difluoride filter membrane, then stabilized for 24 hours. The transparent solution was considered to be NOC. The control OC sample was prepared by dispersion of OC (210 g), surfactant Tween 80 (201 g), and 2,100 mL of purified water. The emulsion was then simply dispersed into 2,500 mL of 0.2% β-cyclodextrin solution without microfluidization. The morphology of nanoemulsions was examined in a transmission electron microscope (Tecnai 12; FEI Company, Eindhoven, the Netherlands). For negative staining, 7 μL of the annealed nanoemulsions were placed on carbon-coated copper grids and washed once with ultrapure water. Then, the samples were stained immediately with 7 μL of 2% uranyl acetate in ultrapure water, washed with water again, and then air-dried. Images were acquired at 120 kV, and the scales were calibrated using a grating replica 3 mm grid. A BioScan camera (model 792 Gatan, Inc, Pleasanton, CA, USA), and Digital-Micrograph™ software (version 3.4; Gatan, Inc, Pleasanton, CA, USA) was used to perform the image capture. The distribution of the NOC particle size was between 20 and 50 nm in diameter ([Figure 1](#f1-ijn-9-301){ref-type="fig"}). The amounts of capsaicinoid (capsaicin plus dihydrocapsaicin) in the OC and NOC were quantified by high-performance liquid chromatography using a modified version of a procedure by Davis et al.[@b12-ijn-9-301] Separation was performed on a C18 column (Zorbax Eclipse XDBC18, 4 × 6 × 250 mm, 5 μm; Agilent Technologies, Santa Clara, CA, USA) with a gradient system. The mobile phase was a mixture of methanol and deionized water at a ratio of 70:30 (v/v). The flow rate was 0.8 mL/minute for 30 minutes, and the ultraviolet/visible detector was set at 280 nm. The amounts of capsaicinoid were 116 mg/g and 120 mg/g in the OC and NOC, respectively. The OC and NOC solutions were freeze dried at −20°C.

Animals and diets
-----------------

Twenty-one male Sprague Dawley rats, 3 weeks of age, were obtained from Daehan Experiment Animals (Eumseong, Korea), and housed individually in stainless steel wire-mesh cages in a room maintained at 22°C±1°C with a 12-hour light/dark cycle (light period: 6 am to 6 pm). Rats were fed laboratory chow and water ad libitum for 1 week to stabilize their metabolic condition. After the 1-week adaptation, the rats were randomly divided into three groups of seven animals each and subsequently maintained on one of the following diets: a HF control diet (HF group) or a HF control diet supplemented with 0.01% (wt:wt) OC (OC group), or 0.01% (wt:wt) NOC (NOC group). The HF control diet (45% of total energy as fat), which contained 23% (wt:wt) fat, 17% (wt:wt) casein, 12% (wt:wt) sucrose, 20% (wt:wt) starch, 15% (wt:wt) dextrose, 6% (wt:wt) cellulose, 4.3% (wt:wt) minerals, and 1.2% (wt:wt) vitamins was based on a modification of the AIN-93 diet.[@b13-ijn-9-301] The rats were maintained on these diets for 14 weeks. Body weight and food intake were monitored twice per week. At the end of the experiment, the rats were fasted overnight and anesthetized with Zoletil:Rompun (4:1) (Bayer, Leverkusen, Germany) at a dose of 0.1 mL/80 g body weight. A central longitudinal incision was made in the abdominal wall, and blood samples were collected by cardiac puncture. Blood samples were centrifuged at 1,500 × *g* for 20 minutes at 4°C, and the plasma was separated and stored at −20°C until analyzed. Liver and epididymal and retroperitoneal WAT were harvested frozen immediately in liquid nitrogen, and stored at −70°C. All experimental protocols were approved by the Animal Experimentation Ethics Committee of the Ewha Womans University, Seoul, Korea for the care and use of laboratory animals (permission number: 2009-8-1).

Plasma biochemical measurements
-------------------------------

Plasma levels of AST, ALT, TC, and TG were determined by enzymatic colorimetric methods using commercial kits in accordance with the manufacturer's instructions.

Hepatic and fecal lipids analyses
---------------------------------

Hepatic and fecal lipids were extracted using the method of Bligh and Dyer,[@b14-ijn-9-301] with slight modifications. Briefly, feces and tissues (500 mg) were homogenized in 1.5 mL of 0.9% saline, and 7.5 mL of methanol:chloroform (2:1, v:v) was added to the homogenates. The mixture was shaken horizontally for 10 minutes and centrifuged at 2,000 × *g* for 10 minutes. The lower chloroform phase was withdrawn, and the lipid in this phase was dried and weighed. TC and TG concentrations were determined by enzymatic colorimetric methods using commercial kits as described above.

Histological analysis
---------------------

Epididymal WAT was dissected from three animals per group and fixed in 10% (v/v) formalin for 24 hours. The fixed samples were washed and embedded in paraffin. Sections 6 μm thick (three sections per rat) were mounted on slides and stained with hematoxylin and eosin stain. The stained sections were observed under a microscope (Olympus, Tokyo, Japan) at 100 × magnification.

Real-time quantitative reverse-transcription polymerase chain reaction
----------------------------------------------------------------------

Total RNA was isolated from WAT using TRIzol® Reagent. The corresponding cDNA was synthesized from 4 μg of RNA using M-MLV reverse transcriptase. After cDNA synthesis, real-time quantitative reverse-transcription polymerase chain reaction was performed using Universal SYBR® Green PCR Master Mix on a fluorometric thermal cycler (Qiagen, Valencia, CA, USA). The sequences of the sense and antisense primers were designed using an online program.[@b15-ijn-9-301] The sequences of the sense and antisense primers used for amplification are shown in [Table 1](#t1-ijn-9-301){ref-type="table"}. The ^ΔΔ^Ct method was used for relative quantification.[@b16-ijn-9-301] The ^ΔΔ^Ct value for each sample was determined by calculating the difference between the Ct value of the target gene and the Ct value of the β-actin reference gene. The normalized level of expression of the target gene in each sample was calculated using the following formula:
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Values were expressed as fold change of the HF group.

AMPK activity assay
-------------------

AMPK activity was performed as described previously,[@b17-ijn-9-301] using an AMPK Kinase Assay kit in accordance with the manufacturer's instructions. Briefly, samples were incubated for 30 minutes at 30°C in a pre-coated plate with a substrate peptide that corresponded to mouse insulin receptor substrates-1 (IRS-1). AMPK activity was measured by monitoring the phosphorylation of Ser 789 in IRS-1 using an anti-mouse phospho-Ser 789 IRS-1 monoclonal antibody and peroxidase-coupled anti-mouse immunoglobulin G. Conversion of the chromogenic substrate tetramethylbenzidine was quantified by measuring the absorbance at 450 nm. Protein was determined using a BCA protein assay kit. Values for AMPK activity were expressed as fold increase of the HF group.

GPDH activity assay
-------------------

GPDH activity was measured with a GPDH activity assay kit in accordance with the manufacturer's instructions. Epididymal WAT was homogenized and centrifuged for 10 minutes at 4°C. GPDH activity was assayed in the supernatant by monitoring the decrease in reduced nicotinamide adenine dinucleotide in the presence of dihydroxyacetone phosphate and measuring absorbance at 340 nm. Protein concentration was determined using a BCA protein assay kit. Values for GPDH activity were expressed as a percentage of the HF group.

Statistical analysis
--------------------

All data are expressed as mean ± standard error of the mean. Statistical analyses were performed using SPSS software (version 17; IBM Corporation, Armonk, NY, USA). Differences among the groups (HF, HF + OC, and HF + NOC) were analyzed by one-way analysis of variance (ANOVA) and Tukey's post hoc multiple comparison tests. *P*-values less than 0.05 were considered to be statistically significant.

Results
=======

Body weight, energy intake, and fat accumulation
------------------------------------------------

At the beginning of the experiment, the initial body weights were not different among the three groups. After 14 weeks of experiment, the final body weight in the NOC-supplemented group was decreased significantly by 10.2%, compared to that in the HF group (*P*\<0.05) ([Table 2](#t2-ijn-9-301){ref-type="table"}). The significant reduction in the body weight of the rats supplemented with NOC was shown after 6 weeks of intervention ([Figure 2A](#f2-ijn-9-301){ref-type="fig"}). The final body weight in the OC-supplemented group tended to be lower than that of the HF group, but the difference was not statistically significant throughout the experiment. NOC supplementation significantly reduced the WAT mass by 17% in comparison with that of the HF group (*P*\<0.01), whereas OC supplementation resulted in no difference in the WAT mass ([Table 2](#t2-ijn-9-301){ref-type="table"}). No significant difference in the amount of energy intake and energy efficiency ratio was observed among the three groups over the study period, which indicates that the beneficial effects of the NOC on body weight and the mass of WAT were not caused by reduced energy consumption ([Table 2](#t2-ijn-9-301){ref-type="table"} and [Figure 2B](#f2-ijn-9-301){ref-type="fig"}).

Plasma, liver, and fecal metabolites
------------------------------------

As shown in [Table 3](#t3-ijn-9-301){ref-type="table"}, rats in the NOC-supplemented group showed significantly lower plasma TG concentration by 31% compared to that of the HF group (*P*\<0.05). However, plasma TG level in the OC-supplemented group was not significantly different compared to that in the HF group. The plasma TC level was not affected by OC and NOC supplementation. Moreover, the levels of TG and TC in the liver and feces were not significantly different among the three groups.

Liver weight and plasma AST and ALT activities
----------------------------------------------

At the doses given, OC and NOC did not cause a rise in plasma AST and ALT activities when compared to those of the HF group ([Table 3](#t3-ijn-9-301){ref-type="table"}). In addition, the liver weight was unaffected by the OC and NOC treatment ([Table 2](#t2-ijn-9-301){ref-type="table"}). These data indicate that OC and NOC were well tolerated by the rats.

Histological analysis
---------------------

The WAT histology was performed to compare the effect of OC and NOC on adipocyte size by hematoxylin and eosin staining. The representative histology of epididymal WAT is shown in [Figure 2C](#f2-ijn-9-301){ref-type="fig"}. The size of epididymal adipocytes was smaller in the OC- and NOC-supplemented groups than in the HF group. In particular, NOC showed a better inhibitory effect on reducing epididymal adipocyte size than OC ([Figure 2C](#f2-ijn-9-301){ref-type="fig"}).

mRNA expression of genes related to adipogenesis, β-oxidation, and thermogenesis
--------------------------------------------------------------------------------

We next analyzed whether OC or NOC supplementation affected mRNA expression of genes involved in adipogenesis in WAT. The mRNA levels of adipogenic genes such as *PPAR-γ*, *SREBP-1c*, and *aP2* showed a 60%, 33%, and 55% decrease, respectively, in the OC-supplemented group compared with those of the HF group ([Figure 3A](#f3-ijn-9-301){ref-type="fig"}). Also, the mRNA levels of *PPAR*-*γ*, *SREBP-1c*, and *aP2* showed a 76%, 47%, and 79% decrease, respectively, in the NOC-supplemented group, compared with those of HF group ([Figure 3A](#f3-ijn-9-301){ref-type="fig"}). *PPAR*-*α*, *CPT*-*1α*, and *UCP2* mRNA levels in WAT were analyzed to compare the effects of OC and NOC on β-oxidation and thermogenesis. The mRNA levels of *PPAR*-*α*, *CPT*-*1α*, and *UCP2* showed 2.92-, 3.8-, and 4.0-fold increase, respectively, in the OC group and 4.01-, 5.19-, and 5.76-fold increase, respectively, in the NOC group, compared with the HF group ([Figure 3B](#f3-ijn-9-301){ref-type="fig"}). Moreover, the NOC-supplemented group showed higher expression of *PPAR*-*α*, *CPT*-*1α*, and *UCP2* mRNA levels by 1.36-, 1.52-, and 1.73-fold, respectively, compared to the OC-supplemented group ([Figure 3B](#f3-ijn-9-301){ref-type="fig"}).

AMPK activity
-------------

Effects of the OC and NOC on AMPK activity was determined in WAT, since AMPK activation affects mRNA expression of genes involved in adipogenesis and thermogenesis. After OC and NOC supplementation, AMPK activity was increased by 1.66- and 2.36-fold, respectively, compared with the HF group (*P*\<0.01). In particular, the activity in the NOC-supplemented group was significantly higher than that in the OC-supplemented group (*P*\<0.01) ([Figure 4A](#f4-ijn-9-301){ref-type="fig"}).

GPDH activity
-------------

We measured GPDH activity in WAT in view of the role of GPDH in adipogenesis. NOC supplementation inhibited GPDH activity by 1.34-fold in comparison to that of the HF group (*P*\<0.05), whereas OC did not result in significant change ([Figure 4B](#f4-ijn-9-301){ref-type="fig"}).

Discussion
==========

A recent study has shown that red pepper constituents are associated with increased energy expenditure and thermogenesis,[@b18-ijn-9-301] resulting in an anti-obesity effect. OC, alcoholic extract of red pepper, is lipophilic and poorly soluble, which means that making use of its effects is a challenging task. Therefore, NOC was developed for improved bioefficacy of OC via enhanced bioavailability of lipophilic OC. The aim of this study was to examine the effects of OC and NOC on obesity, in particular, to assess whether they affect body weight and lipid profiles as well as enzyme activities and gene expression involved in energy metabolism.

Initial experiments were conducted to evaluate whether OC and NOC affected hepatotoxicity. The dose of OC and NOC used in our study was well tolerated by the rats, as demonstrated by the result that plasma levels of AST and ALT were not affected by OC and NOC supplementation. Body weight of the NOC-supplemented group was decreased significantly from 6 weeks after the beginning of the NOC-supplemented diet. The mass of WAT in the NOC-supplemented group was reduced compared to that in the HF group. Energy intake and energy efficiency ratio did not differ among the three groups. These results suggest that the reduction in body weight was not associated with an anorectic effect of the NOC. The OC- and NOC-supplemented groups showed reduction in the size of lipid droplets in adipocytes. WAT stores excess energy as TGs under conditions of energy excess.[@b19-ijn-9-301] Increase in the size and number of adipocytes is a key feature of obesity. Thus, reduction in body weight, which could be attributed partially to a decrease in the mass of the fat pad and size of adipocytes in the NOC-supplemented group, reflected a marked anti-obesity effect of NOC. The final body weight and adipose tissue mass of the OC-supplemented group tended to be lower than those in the HF group, but the difference was not statistically different. These results suggest that NOC efficiently prevented obesity.

Nanoemulsion technology is being increasingly utilized in the food industry to improve stability[@b20-ijn-9-301] and oral bioavailability of lipophilic functional food components.[@b21-ijn-9-301] As an example, the enhanced anti-inflammation activity of curcumin in 79.5 nm nanoemulsion droplets has been reported when compared with curcumin in 618.6 nm emulsion droplets in mice.[@b22-ijn-9-301] In addition, supplementation with nano-sized dietary fiber significantly decreases plasma TG levels in comparison with control mice, whereas other forms of dietary fiber do not.[@b23-ijn-9-301] In a previous study, in vivo pharmacokinetics analysis confirmed that OC nanoemulsions fabricated with chitosan/alginate polymers significantly enhanced the oral bioavailability of OC.[@b24-ijn-9-301] In our experiment, it can be assumed, therefore, that improved bioavailability by using nanoemulsion processing might be one of the ways to explain the greater efficacy of NOC with reduced body weight and suppressed fat accumulation when compared with OC.

Various reports suggest beneficial effects of capsaicin in red pepper on plasma lipid parameters, although some reports question its therapeutic use.[@b18-ijn-9-301],[@b25-ijn-9-301] We have demonstrated herein that NOC effectively reduced the plasma level of TG. There were no differences in lipid concentration in the feces among the three groups. These data imply that reduction of body weight gain and plasma TG level in the NOC group might not result from the increase of TG excretion through lower intestinal TG absorption.

The mRNA levels of genes related to adipogenesis were analyzed in WAT to elucidate the anti-obesity action of OC and NOC. Adipogenesis is the process whereby preadipocytes become mature adipocytes. The rate of adipogenesis is crucial during expansion of WAT and, consequently, development of obesity.[@b26-ijn-9-301] Several transcription factors, including *PPAR-γ* and *SREBP-1c*, control the differentiation of preadipocytes into adipocytes,[@b27-ijn-9-301] which is followed by increased adipogenesis in WAT. aP2, a carrier protein for fatty acids, is also associated with lipid biosynthesis pathways.[@b28-ijn-9-301] In the present study, both OC and NOC significantly downregulated *PPAR*-*γ*, *SREBP-1c*, and *aP2* mRNA expression. These results suggest that the OC and NOC regulated fat accumulation by downregulating the expression of genes associated with adipogenesis and adipocyte differentiation.

Metabolic process that acts favorably on fatty acid oxidation in WAT is accompanied by upregulation of *PPAR*-*α* expression.[@b29-ijn-9-301]*CPT-1* is an enzyme that increases fatty acid oxidation by controlling transfer of long-chain fatty acyl-coenzyme A into the mitochondria.[@b30-ijn-9-301] In our results, *PPAR*-*α* and *CPT*-*1α* mRNA levels were increased following OC and NOC treatment. Moreover, NOC enhanced *PPAR*-*α* and *CPT*-*1α* mRNA levels more efficiently than OC. *UCP2* is expressed in various tissues, including brown adipose tissue, liver, WAT, skeletal muscle, kidney, and lung. Although *UCP2* is not mainly responsible for thermogenic effect, the protein plays a key role in energy metabolism by functioning in adaptive thermogenesis, specifically when *UCP2* is activated fully by endogenous or exogenous environmental effectors.[@b31-ijn-9-301],[@b32-ijn-9-301] Considering that red pepper has an effect on stimulating heat generation,[@b33-ijn-9-301] the increased *UCP2* mRNA level might contribute to the anti-obesity effect of the pepper. In our data, both OC and NOC significantly increased *UCP2* mRNA levels. In addition, NOC supplementation showed higher expression of *UCP2* mRNA level than did OC supplementation. Therefore, it is suggested that increased fatty acid oxidation and energy expenditure as demonstrated by *PPAR-α* and *UCP2* levels might explain the relationship between NOC and its anti-obesity effects.

AMPK is an enzyme that regulates energy metabolism by stimulating catabolic pathways. In response to a decrease in the cellular adenosine triphosphate (ATP)/adenosine monophosphate (AMP) ratio, AMPK becomes activated through phosphorylation of its α-subunit.[@b34-ijn-9-301] Activated AMPK inhibits lipid biosynthetic pathways through downregulation of adipogenic genes such as *SREBP-1c* and *PPAR*-*γ* and stimulates fatty acid oxidation through upregulation of the expression of *PPAR*-*α* and *PGC-1α*.[@b34-ijn-9-301] AMPK activation has also been reported to increase the expression of *UCP2* in skeletal muscle,[@b35-ijn-9-301] suggesting a role of AMPK activation for thermogenesis in the regulation of storage of body fat. In the present study, OC and NOC increased AMPK activity in WAT; moreover, NOC showed more stimulatory effect than OC. In our experiments, the activation of AMPK might have been related to the decreased levels of *SREBP-1c* and *PPAR*-*γ* mRNA and increased levels of *PPAR*-*α* and *UCP2* in the WAT of rats treated with NOC.

GPDH regulates energy metabolism towards the stimulation of lipogenesis by converting dihydroxyacetone phosphate to sn-glycerol-3-phosphate.[@b36-ijn-9-301] In 3T3-L1 adipocytes, red pepper constituents decrease the amount of intracellular TG by inhibiting GPDH activity, which inhibits adipogenesis.[@b37-ijn-9-301] In a previous study, one red pepper constituent, capsaicin, also attenuated GPDH activity, resulting in reduced WAT mass and body weight.[@b36-ijn-9-301] Consistent with those results, NOC supplementation, in the present study, also led to decreased GPDH activity in WAT, whereas OC did not. From these results, it can be hypothesized that NOC is more effective at inhibiting GPDH activity than OC, and that inactivated GPDH may be partially related to anti-obesity effects of NOC.

Conclusion
==========

In the present study, dietary NOC supplementation significantly reduced final body weight with a decreased mass of adipose tissue and ameliorated plasma TG levels in rats with obesity induced by a HF diet. However, the final body weight and WAT mass in the OC-supplemented group was not significantly different compared to those of the HF group. These effects were associated with downregulation of adipogenic gene expression, together with upregulation of gene expression of *PPAR-α*, *CPT-1α*, and *UCP2*, which are involved in β-oxidation and thermogenesis. It is likely that these anti-obesity effects of OC and NOC result from their ability to activate AMPK. In particular, the AMPK activity in the NOC-supplemented group was more stimulated than that of the OC-supplemented group. GPDH activity was more inhibited in the NOC group than the HF group. Meanwhile, there was no significant difference in the activity between the OC and HF group. We assume from these results that NOC might have obesity-preventing effects, which was associated with regulation of the expression of multiple genes, activation of AMPK, and inhibition of GPDH in rats fed a HF diet. Thus, NOC could serve as a promising agent for treatment of obesity.
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![Transmission electron microscope image of the nanoemulsion oleoresin capsicum (scale bar =50 nm).](ijn-9-301Fig1){#f1-ijn-9-301}

![Effects of OC and NOC on diet-induced obesity.\
**Notes:** Changes in (**A**) body weight and (**B**) food intake. (**C**) Representative histological sections of epididymal adipose tissue (hematoxylin and eosin stain; magnification 100×; scale bar =100 μm). Values are expressed as mean ± standard error of the mean (n=7). \**P*\<0.05 versus HF group.\
**Abbreviations:** HF, high-fat; NOC, nanoemulsion oleoresin capsicum; OC, oleoresin capsicum.](ijn-9-301Fig2){#f2-ijn-9-301}

![Effects of OC and NOC on mRNA expression of genes involved in energy metabolism in WAT.\
**Notes:** Relative changes in mRNA levels for genes involved in (**A**) adipogenesis, such as *PPAR*-*γ*, *SREBP-1c*, and *aP2*, and in (**B**) β-oxidation and thermogenesis, such as *PPAR*-*α*, *CPT-1α*, and *UCP2*. Total RNA samples were isolated from different treatment groups and analyzed by real-time PCR, and normalized to β-actin. The value of each control was set at the HF group value and was used to calculate the fold change in each target gene (n=7). \**P*\<0.05; \*\**P*\<0.01 versus HF group; ^\#^*P*\<0.05 versus HF + OC group.\
**Abbreviations:***aP2*, fatty acid-binding protein 2; *CPT*, carnitine palmitoyltransferase; HF, high-fat; NOC, nanoemulsion oleoresin capsicum; OC, oleoresin capsicum; *PPAR*, peroxisome proliferator-activated receptor; *SREBP*, sterol regulatory element-binding protein; *UCP2*, uncoupling protein-2; WAT, white adipose tissue.](ijn-9-301Fig3){#f3-ijn-9-301}

![Effects of OC and NOC on activity of enzymes involved in energy metabolism in WAT.\
**Notes:** (**A**) AMPK activity; (**B**) GPDH activity. AMPK activity was measured using an AMPK kinase kit and normalized to protein content. The activity was expressed as fold increase of the HF group (n=7). GPDH activity was measured using a GPDH kinase kit and normalized to protein content. Values for GPDH activity were expressed as a percentage of the HF group (n=7). \**P*\<0.05; \*\**P*\<0.01 versus HF group; ^\#\#^*P*\<0.01 versus HF + OC group.\
**Abbreviations:** AMPK, AMP-activated protein kinase; GPDH, glycerol-3-phosphate dehydrogenase; HF, high-fat; NOC, nanoemulsion oleoresin capsicum; OC, oleoresin capsicum; WAT, white adipose tissue.](ijn-9-301Fig4){#f4-ijn-9-301}

###### 

Primers used for quantitative real-time polymerase chain reaction (PCR)

  --------------------------------------------------------------------------------------------------------------------------------------
  Name         GenBank no     Primer sequence (5′--3′)   Amplicon size (bp)   Slope     E (%)[a](#tfn1-ijn-9-301){ref-type="table-fn"}
  ------------ -------------- -------------------------- -------------------- --------- ------------------------------------------------
  *aP2*        NM_053365      F: TCACCCCAGATGACAGGAAA\   140                  −3.4928   93.3
                              R: CATGACACATTCCACCACCA                                   

  *β-actin*    NM_031144      F: GGCACCACACTTTCTACAAT\   123                  −3.3235   99.9
                              R: AGGTCTCAAACATGATCTGG                                   

  *CPT-1α*     NM_031559      F: TCGGCAGACCTATTTTGCAC\   143                  −3.2174   104.6
                              R: ATTTGGCGTAGCTGTCGATG                                   

  *PPAR-α*     NM_013196      F: TACCTGTGAACACGATCTGA\   136                  −3.3045   100.7
                              R: GCTAGTCTTTCCTGCGAGTA                                   

  *PPAR-γ*     NM_001145366   F: TGTGGGGATAAAGCATCAGC\   175                  −3.4878   93.5
                              R: CAAGGCACTTCTGAAACCGA                                   

  *SREBP-1c*   AF286470       F: AGGAGGCCATCTTGTTGCTT\   134                  −3.2754   102.0
                              R: GTTTTGACCCTTAGGGCAGC                                   

  *UCP2*       NM_019354      F: ACTGTCGAAGCCTACAAGAC\   111                  −3.4543   94.8
                              R: CACCAGCTCAGTACAGTTGA                                   
  --------------------------------------------------------------------------------------------------------------------------------------

**Note:**

PCR efficiency (E) was calculated according to the equation E=(10^\[−1/slope\]^ − 1) × 100.

**Abbreviations:***aP2*, fatty acid-binding protein 2; *CPT*, carnitine palmitoyltransferase; *PPAR*, peroxisome proliferator-activated receptor; *SREBP*, sterol regulatory element-binding protein; *UCP2*, uncoupling protein-2.

###### 

Effects of OC and NOC on physiological variables

  Variables                                     HF               HF + OC          HF + NOC
  --------------------------------------------- ---------------- ---------------- --------------------------------------------------------------------------------------------------
  Initial body weight (g)                       66.7±1.3         69.7±1.9         69.0±2.5
  Final body weight (g)                         699.9±15.4       662.1±8.1        628.6±22.3[\*](#tfn4-ijn-9-301){ref-type="table-fn"}
  Food intake (g/day)                           25.3±0.4         23.8±0.2         23.7±0.7
  Food efficiency (g gain/g consumed)           0.254±0.005      0.254±0.003      0.241±0.012
  Total food intake (kg/14 weeks)               2.48±0.04        2.33±0.02        2.32±0.07
  Energy intake (kcal/day)                      117.5±1.9        110.6±1.1        109.9±21.8
  Energy efficiency (g gain/kcal consumed)      0.055±0.001      0.055±0.001      0.052±0.001
  Total energy intake (kcal/14 weeks)           11,518.6±188.9   10,839.7±105.1   10,776.3±303.5
  Liver weight (g/100 g body weight)            2.9±0.2          2.9±0.1          3.1±0.1
  Adipose tissue weight (g/100 g body weight)                                     
   Epididymal                                   3.34±0.07        3.58±0.18        3.1±0.13[\#](#tfn6-ijn-9-301){ref-type="table-fn"}
   Retroperitoneal                              4.10±0.26        3.75±0.12        3.34±0.17[\*](#tfn4-ijn-9-301){ref-type="table-fn"}
   Total                                        7.76±0.12        7.32±0.22        6.41±0.27[\*\*](#tfn5-ijn-9-301){ref-type="table-fn"},[\#](#tfn6-ijn-9-301){ref-type="table-fn"}

**Notes:** Values are expressed as mean ± standard error of the mean (n=7).

*P*\<0.05

*P*\<0.01 versus HF group

*P*\<0.05 versus HF + OC group.

**Abbreviations:** HF, high-fat; NOC, nanoemulsion oleoresin capsicum; OC, oleoresin capsicum.

###### 

Effects of OC and NOC on plasma, liver, and fecal metabolites

  Metabolites              HF          HF + OC     HF + NOC
  ------------------------ ----------- ----------- -----------------------------------------------------
  Plasma lipids (mmol/L)                           
   Triglyceride            1.33±0.09   1.17±0.11   0.91±0.10[\*](#tfn9-ijn-9-301){ref-type="table-fn"}
   Total cholesterol       1.41±0.16   1.29±0.13   0.99±0.11
  Liver lipids (μmol/g)                            
   Triglyceride            17.5±1.49   18.9±3.07   18.9±2.50
   Total cholesterol       3.36±0.17   3.08±0.24   3.15±0.16
  Fecal lipids (μmol/g)                            
   Triglyceride            0.80±0.19   0.57±0.13   0.53±0.08
   Total cholesterol       1.22±0.23   1.09±0.29   0.75±0.15
   Plasma AST (IU/L)       56.1±1.6    57.9±2.6    57.9±2.5
   Plasma ALT (IU/L)       21.8±2.3    23.4±3.0    25.4±3.2

**Notes:** Values are expressed as mean ± standard error of the mean (n=7).

*P*\<0.05 versus HF group.

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; HF, high-fat; NOC, nanoemulsion oleoresin capsicum; OC, oleoresin capsicum.

[^1]: \*These authors contributed equally to this work
